ストックスクリーナーアプリを入手
66.61
1.06%
0.70
アフターアワーズ：
66.52
-0.09
-0.14%
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics (CYTK): CEO Blum sells $499k in shares - Investing.com
Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs - stocktitan.net
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake - stocktitan.net
CYTK Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - stocktitan.net
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - stocktitan.net
Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - msn.com
Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - msn.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - GuruFocus
Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus
Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - stocktitan.net
Cytokinetics Inc (HAM:KK3A) Dividend - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics (STU:KK3A) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Cytokinetics (CYTK) 10K Form and Latest SEC Filings 2026 - marketbeat.com
Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - marketbeat.com
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 By Investing.com - Investing.com Canada
Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat
Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com
Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan
Andrew Callos reports multiple 10b5-1 sales for CYTK (NASDAQ: CYTK) - Stock Titan
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Mizuho Boosts Cytokinetics (NASDAQ:CYTK) Price Target to $100.00 - MarketBeat
Cytokinetics Q4 2025 earnings preview - MSN
New Aficamten HCM Data On Exercise Capacity And Flexibility Might Change The Case For Investing In Cytokinetics (CYTK) - simplywall.st
Cytokinetics (CYTK) CEO receives new RSU and stock option awards - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics (CYTK) EVP awarded new stock options and RSUs - Stock Titan
Cytokinetics (CYTK) awards stock options and RSUs to chief legal officer - Stock Titan
Cytokinetics (CYTK) CFO granted RSUs and stock options - Stock Titan
[Form 4] CYTOKINETICS INC Insider Tradi... - Stock Titan
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $75.00 - MarketBeat
CYTK Analyst Update: JP Morgan Raises Price Target to $75 | CYTK Stock News - GuruFocus
Cytokinetics stock price target raised to $75 by JPMorgan - Investing.com Canada
JPMorgan Boosts Price Target on Cytokinetics (CYTK) Amid Positiv - GuruFocus
Granahan Investment Management LLC Purchases Shares of 53,550 Cytokinetics, Incorporated $CYTK - MarketBeat
Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK - National Today
1.52%
0.51%
大文字化:
|
ボリューム (24 時間):